Abstract
Systemic anticoagulation is necessary during extracorporeal membrane oxygenation (ECMO) to prevent circuit clotting. Unfractionated heparin (UFH) is the most widely used anticoagulant for ECMO, but has several clinical disadvantages including risk of development of heparin-induced thrombocytopenia (HIT), need for antithrombin (AT) for maximum effect, and variable dosing in pediatric patients secondary to deficiencies in hemostasis proteins [1, 2]. Direct thrombin inhibitors (DTIs) are potential effective and safe alternatives for anticoagulation in patients undergoing ECMO [3, 4].
| Original language | English (US) |
|---|---|
| Title of host publication | Extracorporeal Membrane Oxygenation |
| Subtitle of host publication | Types, Medical Uses and Complications |
| Publisher | Nova Science Publishers, Inc. |
| Pages | 109-117 |
| Number of pages | 9 |
| ISBN (Electronic) | 9781536190649 |
| State | Published - Dec 21 2020 |
Keywords
- Anticoagulation
- Direct thrombin inhibitors
- ECMO
ASJC Scopus subject areas
- Medicine(all)
- Health Professions(all)